Kalexsyn, Inc. has a state of the art facility located in the heart of Western Michigan University's Technology Resource Park in Kalamazoo Michigan. For directions or to contact us click here or call (269) 488-8488 We have Over 20,000 sq ft of lab space, custom designed medicinal chemistry research facility with open lab plan.Read More
We believe that your projects deserve outstanding chemists skilled in innovation & problem solving.
Bruce H. Lipshutz,* Subir Ghorai, Alexander R. Abela, Ralph Moser, Takashi Nishikata, Christophe Duplais, and Arkady Krasovskiy
Department of Chemistry and Biochemistry, University of California, Santa Barbara, California 93106, United States
Ricky D. Gaston and Robert C. Gadwood*
Kalexsyn, Inc., 4502 Campus Drive, Kalamazoo, Michigan 49008, United States
ABSTRACT: An environmentally benign surfactant (TPGS-750-M), a diester composed of racemic R-tocopherol, MPEG- 750, and succinic acid, has been designed and readily prepared as an effective nanomicelle-forming species for general use in metal-catalyzed cross-coupling reactions in water. Several “name” reactions, including Heck, Suzuki-Miyaura, Sonogashira, and Negishi-like couplings, have been studied using this technology, as have aminations, C-H activations, and olefin metathesis reactions. Physical data in the form of DLS and cryo-TEM measurements suggest that particle size and shape are key elements in achieving high levels of conversion and, hence, good isolated yields of products. This new amphiphile will soon be commercially available.
Synthesis 2012, 44, 2859
Bridged bicyclic morpholines are important building blocks in medicinal chemistry research. The bicyclic morpholine 3-oxa-6-azabicylo[3.1.1]heptane (3a) is of particular interest as a morpholine isostere because it is achiral and shows similar lipophilicity to that of morpholine, based on the cLogP of a derived analogue. The first synthesis of morpholine 3a (tosylate salt) is described; the seven-step sequence begins with inexpensive starting materials and uses straightforward chemistry.
for this article is available online at http://www.thieme-connect.com/ejournals/toc/synthesis.
KALAMAZOO — Kalexsyn Inc. co-founders David Zimmermann and Robert Gadwood have been named Entrepreneurs of the Year by Ernst & Young.
Zimmermann and Gadwood, who formed Kalexsyn in 2003 after Pfizer Inc. purchased Pharmacia Corp., received the award in the technology category for the Michigan and Northwest Ohio region, according to a press release from the company.
Zimmermann is Kalexsyn’s CEO and Gadwood is the company’s president and chief scientific officer.
The award, “which recognizes outstanding entrepreneurs who are building and leading dynamic, growing businesses,” according to the release, was presented at an event in Dearborn on June 10.